Details

Autor(en) / Beteiligte

• Kobayashi, Tohru, Dr
• Saji, Tsutomu, Prof
• Otani, Tetsuya, MD
• Takeuchi, Kazuo, Prof
• Nakamura, Tetsuya, MD
• Arakawa, Hirokazu, Prof
• Kato, Taichi, MD
• Hara, Toshiro, Prof
• Hamaoka, Kenji, Prof
• Ogawa, Shunichi, Prof
• Miura, Masaru, MD
• Nomura, Yuichi, MD
• Fuse, Shigeto, MD
• Ichida, Fukiko, Prof
• Seki, Mitsuru, MD
• Fukazawa, Ryuji, MD
• Ogawa, Chitose, MD
• Furuno, Kenji, MD
• Tokunaga, Hirohide, MD
• Takatsuki, Shinichi, MD
• Hara, Shinya, MD
• Morikawa, Akihiro, Prof

Titel

Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial

Ist Teil von

• The Lancet (British edition), 2012-04, Vol.379 (9826), p.1613-1620

Ort / Verlag

Kidlington: Elsevier Ltd

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Summary Background Evidence indicates that corticosteroid therapy might be beneficial for the primary treatment of severe Kawasaki disease. We assessed whether addition of prednisolone to intravenous immunoglobulin with aspirin would reduce the incidence of coronary artery abnormalities in patients with severe Kawasaki disease. Methods We did a multicentre, prospective, randomised, open-label, blinded-endpoints trial at 74 hospitals in Japan between Sept 29, 2008, and Dec 2, 2010. Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin regimen as the intravenous immunoglobulin group plus prednisolone 2 mg/kg per day given over 15 days after concentrations of C-reactive protein normalised). Patients and treating physicians were unmasked to group allocation. The primary endpoint was incidence of coronary artery abnormalities during the study period. Analysis was by intention to treat. This trial is registered with the University Hospital Medical Information Network clinical trials registry, number UMIN000000940. Findings We randomly assigned 125 patients to the intravenous immunoglobulin plus prednisolone group and 123 to the intravenous immunoglobulin group. Incidence of coronary artery abnormalities was significantly lower in the intravenous immunoglobulin plus prednisolone group than in the intravenous immunoglobulin group during the study period (four patients [3%] vs 28 patients [23%]; risk difference 0·20, 95% CI 0·12–0·28, p<0·0001). Serious adverse events were similar between both groups: two patients had high total cholesterol and one neutropenia in the intravenous immunoglobulin plus prednisolone group, and one had high total cholesterol and another non-occlusive thrombus in the intravenous immunoglobulin group. Interpretation Addition of prednisolone to the standard regimen of intravenous immunoglobulin improves coronary artery outcomes in patients with severe Kawasaki disease in Japan. Further study of intensified primary treatment for this disease in a mixed ethnic population is warranted. Funding Japanese Ministry of Health, Labour and Welfare.